我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

HDAC在心脏病理性重构中的调控机制及意义——“精准医学”模式下的潜在干预靶点

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第5期
页码:
586-591
栏目:
综述
出版日期:
2017-03-25

文章信息/Info

Title:
Mechanism of histone deacetylases in regulation of cardiac pathological remodeling: potential therapeutic target under precision medicine
作者:
李一飞; 华益民; 周开宇
(四川大学华西第二医院儿童心血管科、妇儿疾病与出生缺陷教育部重点实验室，四川 成都 610041)
Author(s):
LI Yi-fei;  HUA Yi-min;  ZHOU Kai-yu
(Department of Pediatric Cardiology & Key Laboratory of Ministry of Education for Women and Children’s Diseases and Birth Defects, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan, China)
关键词:
组蛋白去乙酰化酶; 心力衰竭; 病理性重构; 精准医学
Keywords:
HDAC;  heart failure;  cardiac pathological remodeling;  precision medicine
分类号:
Q556.9
DOI:
-
文献标识码:
A
摘要:
心力衰竭（HF）是多种心血管疾病的最终临床转归，其中心脏病理性重构是HF重要的病理生理基础。目前尚缺乏针对心脏病理性重构的特异性治疗手段，因此目前对于HF的治疗尚无法从本质上改变其生物学特性。组蛋白去乙酰化酶（HDACs）作为一种重要的表观遗传调控机制，已经被证实参与调控多条心脏病理性进程通路。同时多种针对特定HDACs的靶向干预药物已经面试，这为HF的治疗提供了全新的视角和思路。本文将对HDACs在心脏病理性重构中的意义及潜在靶向干预靶点进行综述。
Abstract:
Heart failure is the terminated stage of most kinds of cardiovascular diseases and the cardiac pathological remodeling is the most essential part during such pathophysiological procedure. At present, there is still no specific therapy for heart failure, targeting its biological changes. Histone deacetylases (HDACs) have been proved to be involved in several regulation pathways in pathological process, one important epigenetic mechanism. Moreover, several kinds of targeted medications for specific HDACs have been developed, which provides new insights in treatment of heart failure. In this article, we will summary the functions and regulatory roles of HDACs in cardiac pathological procedure and their potential therapeutic targets.

参考文献/References

[1]陈伟伟,高润霖,刘力生,等.中国心血管病报告2014概要[J].中国循环杂志,2015,30(7):617-622.
[2]Sucharov C,Bristow MR,Port JD.miRNA expression in the failing human heart:functional correlates[J].J Mol Cell Cardiol,2008,45(2):185-192.
[3]Bush EW,McKinsey TA.Targeting histone deacetylases for heart failure[J].Expert Opin Ther Targets,2009,13(7):767-784.
[4]Kao YH,Liou JP,Chung CC,et al.Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure[J].Int J Cardiol,2013,168(4):4178-4183.
[5]Mathiyalagan P,Keating ST,Du XJ,et al.Chromatin modifications remodel cardiac gene expression[J].Cardiovasc Res,2014,103(1):7-16.
[6]Gallo P,Latronico MV,Gallo P,et al.Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure[J].Cardiovasc Res,2008,80(3):416-424.
[7]Sharma RP,Grayson DR,Gavin DP.Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects:analysis of the National Brain Databank microarray collection[J].Schizophr Res,2008,98(1-3):111-117.
[8]Bhakat KK,Izumi T,Yang SH,et al.Role of acetylated human AP-endonuclease(APE1/Ref-1)in regulation of the parathyroid hormone gene[J].EMBO J,2003,22(23):6299-6309.
[9]de Ruijter AJ,van Gennip AH,Caron HN,et al.Histone deacetylases(HDACs):characterization of the classical HDAC family[J].Biochem J,2003,370(Pt 3):737-749.
[10]Liu Z,Li T,Liu Y,et al.WNT signaling promotes Nkx2.5 expression and early cardiomyogenesis via downregulation of Hdac1[J].Biochim Biophys Acta,2009,1793(2):300-311.
[11]Lagger G,O’Carroll D,Rembold M,et al.Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression[J].EMBO J,2002,21(11):2672-2681.
[12]Montgomery RL,Davis CA,Potthoff MJ,et al.Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis,growth, and contractility[J].Genes Dev,2007,21(14):1790-1802.
[13]Cao DJ, Wang ZV,Battiprolu PK,et al.Histone deacetylase(HDAC)inhibitors attenuate cardiac hypertrophy by suppressing autophagy[J].Proc Natl Acad Sci U S A,2011,108(10):4123-4128.
[14]Hang CT,Yang J,Han P,et al.Chromatin regulation by Brg1 underlies heart muscle development and disease[J].Nature,2010,466(7302):62-67.
[15]Zhu W,Trivedi CM,Zhou D,et al.Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness[J].Circ Res,2009,105(12):1240-1247.
[16]Trivedi CM,Luo Y,Yin Z,et al.Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity[J].Nat Med,2007,13(3):324-331.
[17]Kook H,Lepore JJ,Gitler AD,et al.Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop[J].J Clin Invest,2003,112(6):863-871.
[18]Kee HJ,Eom GH,Joung H,et al.Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy et al[J].Circ Res,2008,103(11):1259-1269.
[19]Kee HJ,Kook H.Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy[J].J Mol Cell Cardiol,2009,47(6):770-780.
[20]Glenn DJ,Wang F,Chen S,et al.Endothelin-stimulated human B-type natriuretic peptide gene expression is mediated by Yin Yang 1 in association with histone deacetylase 2[J].Hypertension,2009,53(3):549-555.
[21]Trivedi CM,Lu MM,Wang Q,Epstein JA.Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy[J].J Biol Chem,2008,283(39):26484-26489.
[22]Montgomery RL,Potthoff MJ,Haberland M,et al.Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice[J].J Clin Invest,2008,118(11):3588-3597.
[23]Samant SA,Courson DS,Sundaresan NR,et al.HDAC3-dependent reversible lysine acetylation of cardiac myosin heavy chain isoforms modulates their enzymatic and motor activity[J].J Biol Chem,2011,286(7):5567-5577.
[24]McKinsey TA.The biology and therapeutic implications of HDACs in the heart[J].Handb Exp Pharmacol,2011,206:57-78.
[25]Sucharov CC,Langer S,Bristow M,et al.Shuttling of HDAC5 in H9C2 cells regulates YY1 function through CaMKIV/PKD and PP2A[J].Am J Physiol Cell Physiol,2006,291(5):C1029-C1037.
[26]Backs J,Song K,Bezprozvannaya S,et al.CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy[J].J Clin Invest,2006,116(7):1853-1864.
[27]Vega RB,Matsuda K,Oh J,et al.Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis[J].Cell,2004,119(4):555-566.
[28]Gupta MP,Samant SA,Smith SH,et al.HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity[J].J Biol Chem,2008,283(15):10135-10146.
[29]Granger A,Abdullah I,Huebner F,et al.Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice[J].FASEB J,2008,22(10):3549-3560.
[30]Chang S,McKinsey TA,Zhang CL,et al.Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development[J].Mol Cell Biol,2004,24(19):8467-8476.
[31]Fang J,Li Y,Zhou K,et al.Antithetical regulation of alpha-myosin heavy chain between fetal and adult heart failure though shuttling of HDAC5 regulating YY-1 function[J].Cardiovasc Toxicol,2015,15(2):147-156.
[32]Margariti A,Zampetaki A,Xiao Q,et al.Histone deacetylase 7 controls endothelial cell growth through modulation of beta-catenin[J].Circ Res,2010,106(7):1202-1211.
[33]Kawamura T,Ono K,Morimoto T,et al.Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes[J].J Biol Chem,2005,280(20):19682-19688.
[34]Karamboulas C,Swedani A,Ward C,et al.HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage[J].J Cell Sci,2006,119(Pt 20):4305-4314.
[35]Choi SY,Ryu Y,Kee HJ,et al.Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes[J].Vascul Pharmacol,2015,72:130-140.
[36]Antos CL,McKinsey TA,Dreitz M,et al.Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors[J].J Biol Chem,2003,278(31):28930-28937.
[37]Kong Y,Tannous P,Lu G,et al.Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy[J].Circulation,2006,113(22):2579-2588.
[38]Piekarz RL,Frye AR,Wright JJ,et al.Cardiac studies in patients treated with depsipep- tide,FK228,in a phase II trial for T-cell lymphoma[J].Clin Cancer Res,2006,12(12):3762-3773.

备注/Memo

备注/Memo:
收稿日期：2016-07-09.
基金项目：国家自然科学基金项目资助（81270226；81570369；81571515）；长江学者和创新团队发展计划项目资助（IRT0935）
通讯作者：周开宇，副主任医师，主要从事胎儿及儿童心脏疾病研究 Email：kaiyuzhou313@163.com
作者简介：李一飞，主治医师，博士 Email：liyfwcsh@scu.edu.com
更新日期/Last Update: 2017-04-20